Phase II trial of chronic oral ZD 1839 (IRESSA) (NSC-715055) in both previously-untreated and previously-treated patients with selected stage IIIB and IV bronchioloalveolar carcinoma (BAC).
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2012
At a glance
- Drugs Gefitinib (Primary)
- Indications Adenocarcinoma; Bronchiolo-alveolar adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 17 Sep 2005 New trial record.